Report Overview

The Kenya Sleep Management Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Kenya is undergoing rapid demographic and epidemiological transition, and incidence of sleep disorders is increasing due to the transition. Sleep disorders are a group of conditions that affect the ability to sleep well on a regular basis. The lack of sleep can have a negative impact on energy, mood, concentration, and overall health. The most common sleep disorder is insomnia. It can be caused by stress and anxiety, hormones, digestive problems, or underlying chronic diseases. In a study conducted in Kenya, the prevalence of self-reported sleep problems was consistently higher in women than men. There are a number of potential explanations for these sex differences in sleep problems, such as different physiology, greater burden of psychologic comorbidity (anxiety, depression) in women, gender-specific roles such as mothering and related stresses, disparities in socioeconomic status and social role.



Market Drivers

The market is majorly driven by the rise in the incidence of sleep disorders in low- and middle- income countries like Kenya. This can be attributed to lifestyle changes due to rapid urbanization and increase in smoking among young population that disturbs the circadian cycle of the body. Kenya saw Prevalence Rate of Sleep disorders between 8.3 percent and 12.7 percent.

Loss in nocturnal sleep may also be due to the presence of chronic pain conditions like osteoarthritis, rheumatoid arthritis, and cancer pain. Sedatives induce calming effects and are usually prescribed to help patients suffering from chronic illnesses sleep.

Growing interest of industry players for developing superior quality sleep inducing drugs will elevate the sleep management drugs market growth. Key players such as Merck & Co. and others have focused on launching new formulations that will enhance the sleep activity in individuals suffering from chronic sleeping disorders such as insomnia sleep apnoea and narcolepsy. For instance, Merck introduced new drug (Belsomra) for treating insomnia that gained momentum and was highly prescribed by the healthcare professionals for treating insomnia.

The aforementioned factors will escalate growth in the sleep management drugs market in Kenya in the forecast period.

However, Sedatives and Antidepressants tend to develop dependence on the drugs among patients and also have side-effects like stroke and heart attack may hamper growth of the sleep management drugs market.